curanexpharma.com (CURX): Debt to Book Capitalization Ratio

Corporate company logo of Curanex Pharmaceuticals (CURX)

The percentage of debt participation in the balance sheet capital of Curanex Pharmaceuticals Inc (CURX) demonstrates credit leverage dynamics, where the value 0.06 serves as a baseline reliability indicator. Curanex Pharmaceuticals Inc (CURX) relies on developing agents for long-term gastrointestinal therapy protected by patents. However, R&D activity is currently minimal and limited to licensing. Sales stability is maintained through specialized climate-controlled delivery via pharmacy chains.

CURX Curanex Pharmaceuticals: Debt to Book Value in the range 08/27/2025 - 10/29/2026

Comprehensive metric breakdowns and analytics for curanexpharma.com (CURX)

- current price and projected stock value:
Stock Price Curanex Pharmaceuticals|CURX - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value CURX|CURX - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Curanex Pharmaceuticals|CURX - Company Net Assets|Market Capitalization to Book Value Ratio curanexpharma.com|CURX - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Curanex Pharmaceuticals Inc|CURX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Curanex Pharmaceuticals|CURX - Company Total Indebtedness|Debts to Book Capitalization CURX|CURX - Long-Term Debt Volume|Company Current Liabilities Curanex Pharmaceuticals|Quick Ratio curanexpharma.com
- business earnings and investment ratios data:
CURX - Net Income
Basic company analysis:Curanex CURX
Manufactured products of curanexpharma.com

This ratio determines the extent to which the capital structure depends on borrowed funds. By analyzing the trend of liabilities to book capitalization, an investor assesses the risk of excessive leverage. The metric is calculated as the ratio of total debt to total equity. For Curanex Pharmaceuticals Inc (CURX), a low level of borrowing is critically important, as it creates a financial buffer during raw material supply chain disruptions and challenges with foreign patent protection.

Analysis of competing companies

Debts to Book Capitalization PHAT (Phathom Pharmaceuticals)|Debts to Book Capitalization ternspharma.com TERN|IRWD - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio IMRN (Immuron Limited)|Evoke Pharma, Inc (EVOK) - Debt to Book Capitalization Ratio|Debt to Book Value Entero Therapeutics|RDHL (RedHill Biopharma Ltd) - Debts to Book Capitalization|Debts to Book Capitalization Palisade Bio Inc.|Debt to Book Value JAGX (Jaguar Health)|BIOR (Biora Therapeutics Inc.) - Debt to Net Assets Ratio|Debts to Book Capitalization MORF (Morphic Holding Inc)